Medication info
Telmisartan Rosuvastatin/Ezetimibe Tablets 40/10/10 mg

Telmisartan Rosuvastatin/Ezetimibe Tablets 40/10/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium Micronized›10.4mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Pink, egg-shaped film-coated tablet
Packaging
30 tablets/bottle, 3 tablets/bottle, 30 tablets/PTY, 10 tablets/PTY
Approval status
Active

MFDS item code 202202205 · Approved 2022.05.24 · Insurance code 643308980

Summary

Main use
Treatment of essential hypertension, improvement of dyslipidemia, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When telmisartan is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. Following a dose increase, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of telmisartan is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating telmisartan treatment to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. ∘ Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed telmisartan 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted in patients who require a greater reduction in LDL-cholesterol. After starting treatment with the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of 4 weeks or longer and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Treatment of essential hypertension, improvement of dyslipidemia, and prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • myocardial infarction
  • primary hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
View approved original text

This drug is prescribed for patients who need to use two drugs, telmisartan and rosuvastatin/ezetimibe, simultaneously. Telmisartan is mainly used for the treatment of essential hypertension and has the effect of reducing the risk of cardiovascular diseases. It particularly lowers the risk of cardiovascular complications such as myocardial infarction or stroke in high-risk patients over 55 years of age who cannot use ACE inhibitors. Rosuvastatin/ezetimibe helps control cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia, reducing blood levels of bad cholesterol (LDL-C) and triglycerides, and increasing good cholesterol (HDL-C). This combination of medications is used to improve cardiovascular health and effectively manage the risk of related diseases.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of telmisartan and the rosuvastatin/ezetimibe combination. Take 1 tablet once daily with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). ○ Telmisartan 1. Essential hypertension Adults: The recommended dose of telmisartan is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When telmisartan is administered concomitantly with thiazide diuretics such as hydrochlorothiazide, it provides an additional blood pressure-lowering effect. Following a dose increase, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of telmisartan is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating telmisartan treatment to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. ∘ Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed telmisartan 40 mg once daily. ○ Rosuvastatin/ezetimibe The rosuvastatin/ezetimibe combination is administered once daily, with or without food. Patients should continue a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination. The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL-cholesterol level, recommended treatment goal, and response. Primary hypercholesterolemia The dosage range of the rosuvastatin/ezetimibe combination is 5/10mg∼20/10mg once daily. The recommended initial dose is 5/10mg once daily. The dose may be adjusted in patients who require a greater reduction in LDL-cholesterol. After starting treatment with the rosuvastatin/ezetimibe combination or adjusting the dose, check blood lipid levels at intervals of 4 weeks or longer and adjust the dose accordingly; the dose may be increased to a maximum of 20/10mg once daily. Patients taking telmisartan and the rosuvastatin/ezetimibe combination concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during pregnancy; therefore, treatment should be stopped immediately upon confirmation of pregnancy. Additionally, some components of this medication may rarely cause kidney damage due to muscle breakdown, so the drug should be stopped or temporarily discontinued if symptoms of acute severe muscle problems or conditions with a high risk of muscle damage occur. Patients who are allergic to any ingredients of this drug, those with severe liver dysfunction, muscle disorders, specific renal function impairment, pregnant or breastfeeding women, and cases where certain drugs should not be used concurrently should not take this medication. Since liver and muscle issues can arise, patients with weak liver function or a history of liver disease should undergo liver function tests before taking the drug and continue to have regular check-ups during treatment. If symptoms like muscle pain, muscle weakness, fatigue, fever, etc., occur, they should inform a doctor immediately and undergo testing, especially if muscle enzyme levels are significantly elevated, treatment should be discontinued. Elderly patients, those with diabetes, kidney disease, and hypothyroidism are at higher risk of muscle damage and should use caution during treatment. Blood pressure may drop too low, leading to symptoms of dizziness or fainting; therefore, patients should consult medical personnel immediately if they experience these symptoms after taking the medication. This drug may interact with other medications, so patients should inform their doctor or pharmacist of any other medications they are currently taking. Additionally, this medication may increase blood potassium levels, so patients at risk of hyperkalemia need regular blood tests. Caution is needed as dizziness may occur while driving or operating machinery. It is important to continue an appropriate diet regimen while taking this medication and to identify and treat other causes of dyslipidemia. Regular monitoring of liver function and muscle status before and during the use of this medication is essential, and treatment should be stopped immediately if abnormalities are found.

Side effects

Gastritis, gastroesophageal reflux disease, hemorrhoids, colon polyps, vomiting, headache, increased ALT, increased AST, chest pain, facial swelling, strange sensation, drug intolerance, irritable bowel syndrome, esophagitis, dizziness, drowsiness, neurodegenerative disorders, orthostatic dizziness, migraine, diabetes, glucose tolerance disorder, depression, bronchitis, rhinitis, cystitis, onychomycosis, soft tissue infection, hepatic steatosis, liver dysfunction, liver toxicity, acute hepatitis, toxic hepatitis, increased gamma-glutamyl transferase, elevated blood cholesterol, increased serum alkaline phosphatase, irregular heart rate, osteoarthritis, osteoporosis, musculoskeletal stiffness, musculoskeletal discomfort, muscle weakness, cold sweat, dermatitis, skin burning sensation, skin disorders, alopecia, oropharyngeal pain, nasal congestion, respiratory difficulties, pelvic pain, breast cysts, eyelid drooping, diabetic retinopathy, ear discomfort, kidney function impairment, benign esophageal neoplasm, upper respiratory tract infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, abdominal discomfort, dry mouth, liver function abnormalities, liver impairment, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle spasms, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated serum creatine kinase, decreased hemoglobin, facial spasms, sensory disturbances, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, drowsiness, neurodegenerative disorders, cough, hyperventilation, pneumonia, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, insomnia, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, chest discomfort, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. Storing it this way will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink, egg-shaped film-coated tablet

Package unit

30 tablets/bottle, 3 tablets/bottle, 30 tablets/PTY, 10 tablets/PTY

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.